Tabouret, E.; Wang, H.; Amin, N.; Jung, J.; Appay, R.; Cui, J.; Song, Q.; Cardone, A.; Park, D.M.; Gilbert, M.R.;
et al. Correction: Tabouret et al. TP5, a Peptide Inhibitor of Aberrant and Hyperactive CDK5/p25: A Novel Therapeutic Approach against Glioblastoma. Cancers 2020, 12, 1935. Cancers 2025, 17, 3094.
https://doi.org/10.3390/cancers17193094
AMA Style
Tabouret E, Wang H, Amin N, Jung J, Appay R, Cui J, Song Q, Cardone A, Park DM, Gilbert MR,
et al. Correction: Tabouret et al. TP5, a Peptide Inhibitor of Aberrant and Hyperactive CDK5/p25: A Novel Therapeutic Approach against Glioblastoma. Cancers 2020, 12, 1935. Cancers. 2025; 17(19):3094.
https://doi.org/10.3390/cancers17193094
Chicago/Turabian Style
Tabouret, Emeline, Herui Wang, Niranjana Amin, Jinkyu Jung, Romain Appay, Jing Cui, Qi Song, Antonio Cardone, Deric M. Park, Mark R. Gilbert,
and et al. 2025. "Correction: Tabouret et al. TP5, a Peptide Inhibitor of Aberrant and Hyperactive CDK5/p25: A Novel Therapeutic Approach against Glioblastoma. Cancers 2020, 12, 1935" Cancers 17, no. 19: 3094.
https://doi.org/10.3390/cancers17193094
APA Style
Tabouret, E., Wang, H., Amin, N., Jung, J., Appay, R., Cui, J., Song, Q., Cardone, A., Park, D. M., Gilbert, M. R., Pant, H., & Zhuang, Z.
(2025). Correction: Tabouret et al. TP5, a Peptide Inhibitor of Aberrant and Hyperactive CDK5/p25: A Novel Therapeutic Approach against Glioblastoma. Cancers 2020, 12, 1935. Cancers, 17(19), 3094.
https://doi.org/10.3390/cancers17193094
